Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01191684 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer
A Phase 1 study of Stage III Pancreatic Cancer and Recurrent Colon Cancer, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT01191684 is a Phase 1 study of Stage III Pancreatic Cancer and Recurrent Colon Cancer that has completed, run by City of Hope Medical Center. The registered enrollment target is 12 participants, below the 166-participant average among 13 other Stage III Pancreatic Cancer trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01191684, a Phase 1 study of Stage III Pancreatic Cancer and Recurrent Colon Cancer, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with colorectal, stomach, or pancreatic cancer.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- OTHER flow cytometry
- OTHER immunoenzyme technique
- OTHER enzyme-linked immunosorbent assay
- BIOLOGICAL modified vaccinia virus ankara vaccine expressing p53
Study Locations (1)
California
- City of Hope Medical Center - Duarte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2011-10 |
| Est. Completion | 2013-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01191684
The ClinicalTrials.gov registry entry for NCT01191684 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 166-participant average among 13 other Stage III Pancreatic Cancer trials with a reported enrollment target (93% lower). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Stage III Pancreatic Cancer appearing as the primary indexed condition, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT01191684 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01191684 about?
NCT01191684 is a clinical study titled "Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer". RATIONALE: Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with colorectal, stomach, or pancreatic cancer.
What is the current status of trial NCT01191684?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2011-10. Estimated completion is 2013-08.
What conditions does trial NCT01191684 study?
This clinical trial studies the following conditions: Stage III Pancreatic Cancer, Recurrent Colon Cancer, Recurrent Rectal Cancer, Recurrent Pancreatic Cancer, Stage III Colon Cancer.
What interventions are being tested in trial NCT01191684?
The interventions under investigation include: laboratory biomarker analysis (OTHER), flow cytometry (OTHER), immunoenzyme technique (OTHER), enzyme-linked immunosorbent assay (OTHER), modified vaccinia virus ankara vaccine expressing p53 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01191684?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01191684 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage III Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer
COMPLETED · Phase 1
-
BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer
COMPLETED · Phase 1
-
Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers
COMPLETED · Phase 1
-
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.